Press Releases :: ProMIS Neurosciences, Inc. (PMN)

Sep 13, 2017

ProMIS Neurosciences Designates PMN330 as Third, Validated Lead Product for Development in Alzheimer's Disease

Aug 28, 2017

ProMIS Neurosciences Completes Second Closing of Private Placement

Aug 11, 2017

ProMIS Neurosciences Announces Second Quarter 2017 Results

Jul 5, 2017

ProMIS Neurosciences to Present Preclinical Data from Alzheimer's Disease Program at AAIC 2017

Jun 6, 2017

ProMIS™ Neurosciences Appoints William C. Mobley to Scientific Advisory Board

May 31, 2017

ProMIS Neurosciences Identifies Novel Therapeutic Epitope Target for ALS and Dementia

May 25, 2017

Prion 2017: Deciphering Neurodegenerative Disorders - 23-26 May 2017 Edinburgh

May 24, 2017

ProMIS Neurosciences Designates PMN350 its Second Lead Product for Development in Alzheimer's Disease